Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of HRS-1893 in Healthy Volunteers and oHCM Patients
NCT05879523Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-1893 in hypertrophic cardiomyopathy (HCM) (4 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoint: incidence of adverse event (AE), serious adverse event (SAE) at 34 days. Started Jun 2023; status: completed.
02
Drugs
HRS-1893
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT05879523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879523.